Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms

Journal of Bone and Mineral Research

Volumn 25, Issue 11, 2010, Pages 2427-2437

  Jilka, Robert L ^a   O'Brien, Charles A ^a   Bartell, Shoshana M ^a   Weinstein, Robert S ^a   Manolagas, Stavros C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

bone remodeling; hyperparathyroidism; osteoblasts; osteoclasts; parathyroid hormone; sRANKL

Indexed keywords

GROWTH FACTOR; NAKED CUTICLE 2 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; SCLEROSTIN; TWIST1 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT1 INDUCIBLE SIGNALING PATHWAY PROTEIN 1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BONE REMODELING; CANCELLOUS BONE; CELL COUNT; CONTROLLED STUDY; GENE TARGETING; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SWISS WEBSTER MOUSE; VERTEBRA;

ANIMALS; BODY WEIGHT; BONE MARROW; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CALCIUM; CELL COUNT; FEMALE; GENETIC MARKERS; HUMANS; MICE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE; RANK LIGAND; SIGNAL TRANSDUCTION; SOLUBILITY; SPINE; WNT PROTEINS;

EID: 78349263788     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.145     Document Type: Article

References (52)

1. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F,. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16: 1575 -1582.
2. Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009; 174: 239 -247.
3. Parisien M, Dempster DW, Shane E, Bilezikian JP,. Histomorphometric analysis of bone in primary hyperparathyroidism. In:, Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids. Basic and Clinical Concepts. San Diego, CA: Academic Press, 423 -436. 2001.
4. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008; 23: 2018 -2024.
5. Mosekilde L,. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008; 69: 1 -19.
6. Kearns AE, Khosla S, Kostenuik PJ,. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008; 29: 155 -192.
7. O'Brien CA,. Control of RANKL gene expression. Bone. 2010; 46: 911 -919.
8. Galli C, Zella LA, Fretz JA, et al. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology. 2008; 149: 146 -153.
9. Bonewald LF, Mundy GR,. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 1990; 261 -276.
10. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA,. Local communication on and within bone controls bone remodeling. Bone. 2009; 44: 1026 -1033.
11. Tang Y, Wu X, Lei W, et al. TGF-b1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15: 757 -765.
12. Walker EC, McGregor NE, Poulton IJ, et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008; 23: 2025 -2032.
13. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ,. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008; 105: 20764 -20769.
14. Yuan YY, Kostenuik PJ, Ominsky MS, et al. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int. 2008; 19: 625 -635.
15. Lloyd SA, Yuan YY, Kostenuik PJ, et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int. 2008; 82: 361 -372.
16. Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network Analysis. J Biol Chem. 2007; 282: 33086 -33097.
17. Qin L, Qiu P, Wang L, et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 2003; 278: 19723 -19731.
18. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148 -158.
19. Rodda SJ, McMahon AP,. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133: 3231 -3244.
20. Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22: 2968 -2979.
21. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577 -4583.
22. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3: e2942. doi:10.1371/journal.pone.0002942.
23. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578 -588.
24. Jilka RL,. Inhibiting the inhibitor: a new route to bone anabolism. J Bone Miner Res. 2009; 24: 575 -577.
25. Brandi ML, Collin-Osdoby P,. Vascular biology and the skeleton. J Bone Miner Res. 2006; 21: 183 -192.
26. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007; 131: 324 -336.
27. Park JH, Song HI, Rho JM, et al. Parathyroid hormone (1-34) augments angiopoietin-1 expression in human osteoblast-like cells. Exp Clin Endocrinol Diabetes. 2006; 114: 438 -443.
28. Rashid G, Bernheim J, Green J, Benchetrit S,. Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest. 2008; 38: 798 -803.
29. Grey A, Mitnick MA, Masiukiewicz U, et al. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology. 1999; 140: 4683 -4690.
30. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278: 50259 -50272.
31. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595 -610.
32. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281: 1509 -1512.
33. Fu Q, Jilka RL, Manolagas SC, O'Brien CA,. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem. 2002; 277: 48868 -48875.
34. Lotinun S, Sibonga JD, Turner RT,. Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology. 2005; 146: 4074 -4081.
35. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC,. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009; 44: 275 -286.
36. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC,. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007; 22: 1492 -1501.
37. Jackson A, Vayssiere B, Garcia T, et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone. 2005; 36: 585 -598.
38. Li X, Warmington K, Niu Q-T, et al. 2009 Increased bone formation and bone mass by sclerostin antibody was not blunted by pretreatment with alendronate in ovariectomized rats with established osteopenia. J Bone Miner Res 24: Available at.
39. Burkhardt R, Bartl R, Frisch B, et al. The structural relationship of bone forming and endothelial cells of the bone marrow. In:, Arlet J, Ficat RP, Sungerford DS, eds. Bone Circulation. Williams & Wilkins, Baltimore: pp. 2 -14. 1984.
40. Brunner S, Theiss HD, Murr A, Negele T, Franz WM,. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. Am J Physiol Endocrinol Metab. 2007; 293: E1670 -E1675.
41. Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood. 2010; 115: 140 -149.
42. Langer M, Prisby R, Peter Z, Boistel R, Lafage-Proust MH, Peyrin F,. Quantitative investigation of bone microvascularization from 3D synchrotron micro-computed tomography in a rat model. Conf Proc IEEE Eng Med Biol Soc. 2009; 1: 1004 -1007.
43. Zaruba MM, Huber BC, Brunner S, et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res. 2008; 77: 722 -731.
44. Zerlin M, Julius MA, Kitajewski J,. Wnt/Frizzled signaling in angiogenesis. Angiogenesis. 2008; 11: 63 -69.
45. Maretto S, Cordenonsi M, Dupont S, et al. Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A. 2003; 100: 3299 -3304.
46. Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor a pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007; 117: 1616 -1626.
47. Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development. 2002; 129: 1893 -1904.
48. Wan C, Gilbert SR, Wang Y, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A. 2008; 105: 686 -691.
49. Hsu HL, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999; 96: 3540 -3545.
50. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC,. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998; 13: 793 -802.
51. Chen HL, Demiralp B, Schneider A, et al. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem. 2002; 277: 19374 -19381.
52. Samadfam R, Xia Q, Goltzman D,. Cotreatment of parathyroid hormone with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res. 2007; 22: 55 -63.